Navigation Links
Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
Date:10/30/2008

SUNNYVALE, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its first fiscal quarter ended September 30, 2008. The net loss for the first quarter of fiscal 2009, was $6.5 million, or $0.25 per share, compared to a net loss of $6.8 million, or $0.26 per share, in the first quarter of fiscal 2008.

Total operating expenses were $6.6 million in the first quarter of fiscal 2009, including $1.4 million of severance related share-based compensation expense and $0.5 million of severance expense. Excluding the $1.9 million of severance related share-based compensation and severance expenses, total expenses were $4.7 million in the first quarter of fiscal 2009 compared to $7.3 million for the first quarter of fiscal 2008, a decrease of $2.6 million. Excluding $1.4 million in severance related share-based compensation expense, share-based compensation expense was $0.4 million in the first quarter of fiscal 2009 compared to $0.7 million in the first quarter of fiscal 2008. The decrease of $2.6 million in total operating expenses, after excluding the severance related expenses, in the first quarter of fiscal 2009 was primarily due to reduced personnel expenses due to lower headcount and reduced manufacturing costs and outside preclinical expenses associated with the company's HDAC, Btk and Factor VIIa inhibitor programs.

As of September 30, 2008, the company's cash, cash equivalents and marketable securities totaled $12.5 million compared to $16.8 million at June 30, 2008.

Robert W. Duggan stated, "Entering my second month as Chairman and Interim CEO, there are a few observations I wish to share with my fellow stakeholders. Pharmacyclics is a company consisting of hi
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
2. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
3. Pharmacyclics Announces It Received Nasdaq Notification
4. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
5. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. United Therapeutics Reports Third Quarter 2008 Financial Results
8. BioMed Realty Trust Reports Third Quarter 2008 Financial Results
9. Varian, Inc. Reports Strong Fourth Quarter 2008 Results
10. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
11. VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Dallas, Texas (PRWEB) July 30, 2014 ... in Private Equity and Venture Capital Funding” report ... factors shaping the private equity and venture capital ... that these are expected to have significant impact ... the US and globally. Furthermore, the report identifies ...
(Date:7/29/2014)... The advanced optical methods and applications for imaging ... revolution in the neurosciences were the inspiration behind ... SPIE, the international society for optics and photonics . ... the BRAIN Initiative in the United States, and a ... for and provide examples of the impact that optics ...
(Date:7/29/2014)... , July 29, 2014 Human Longevity, Inc. ... company focused on extending the healthy, high performance human ... Och , Ph.D., an expert in machine learning and ... comes to HLI from Google where he was Distinguished ... will report directly to HLI Co-Founder and CEO, ...
(Date:7/29/2014)... 2014) Tough, ultralight foam of atom-thick sheets can ... chemical process invented at Rice University. , In ... nanoscale building, with floors and walls that reinforce each ... materials: floors and walls of graphene oxide that self-assemble ... , The researchers say the foam could find use ...
Breaking Biology Technology:Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3Tough foam from tiny sheets 2
... Vical Incorporated,(Nasdaq: VICL ) presentation at the ... at 1 p.m. Eastern Daylight Time, will be ... page at http://www.vical.com ., About Vical, ... on its,patented DNA delivery technologies for the prevention ...
... - Oncentra(R) RT Viewer* Officially to Launch ... ASTRO 2008, Boston, USA, September,21-24, Nucletron, a ... release of Oncentra RT Viewer. This unique innovation,in ... review,radiotherapy plans that are generated with a wide ...
... significant partial onset seizure reduction, proven ... - Keppra XR(TM) is ... press release, regulated information:,UCB announced today that the U.S. Food ... for use as,an add-on to other antiepileptic treatments for people ...
Cached Biology Technology:Vical to Present at UBS Global Life Sciences Conference 2Nucletron Announces Market Release of First Commercially Available Software to Review and Share Dicom-Based Treatment Plans for Radiotherapy 2Video: Keppra XR(TM) Approved in the U.S. 2Video: Keppra XR(TM) Approved in the U.S. 3Video: Keppra XR(TM) Approved in the U.S. 4
(Date:7/30/2014)... spinal cord injury (SCI), traumatic brain injury (TBI) and ... has been learned over the past 30 years regarding ... regulate axon growth, but this large body of information ... Lemmon and his team from University of Miami in ... but a consensus is emerging that one contributing factor ...
(Date:7/30/2014)... The analysis of the roughly 3,000 pieces is still ... that the results will be of major significance. "Amazingly ... insect species in Fushun amber that we found in ... , The Baltic amber comes from the Baltic ... Sites rich in finds are, e.g., the coastal regions ...
(Date:7/30/2014)... unveiled the first high-resolution map of the carbon ... of Per. The new and improved methodology used ... for future market-based carbon economies. The new ... diversity and it provides the critical input to ... land use, and enforcement purposes. The technique includes ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... Theres more to biofuels than the food vs. fuel debate ... And so Steven Fales, a professor of agronomy ... Iowa States Bioeconomy Institute, organized and moderated a three-hour symposium ... American Association for the Advancement of Science in Boston. ...
... theory into practice to manage complex and closely linked ... challenge, but one NOAA researcher Anne Guerry says can ... value of our ocean resources. Guerry will ... people obtain from ecosystems, in managing marine resources in ...
... This release is available in French . , ... the University of Toronto to rev up the production of stem ... cells and embryonic stem cells. The end products are blood and ... they form beating tissue. To do this, he has ...
Cached Biology News:Iowa Staters talk biofuels, healthy oils and 'pharma crops' at AAAS meeting 2Can Dungeness crab and eelgrass help improve management of our marine resources? 2From stem cells to organs: The bioengineering challenge 2
Proline-serine-threonine phosphatase-interacting protein 2...
E2F2 protein...
Anti-gamma Glutamyl Transferase (gammaGT) Host: mouse monoclonal Species Reactivity: human Applications: WB, IP, FC Storage: 4C...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Biology Products: